Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment
By Ben Glickman
Roche Group-member Genentech said Thursday it had received regulatory approval for its treatment for patients with an early-stage form of lung cancer.
The South San Francisco, Calif.-based company said that the U.S. Food and Drug Administration had approved Alecensa in treating patients with anaplastic lymphoma kinase-positive non-small cell lung cancer who have already had tumor resection.
Alecensa is currently approved as a first- and second-line treatment for ALK-positive metastatic non-small cell lung cancer, the company said. In February, Roche reported U.S. sales of Alecensa of 467 million Swiss francs ($511.8 million).
The company said the approval was based on results from a Phase 3 study, which showed that Alecensa reduced risk of disease recurrence or death by 76%, as compared with platinum-based chemotherapy.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 18, 2024 18:03 ET (22:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase